01-08-2012 | PHASE I STUDIES
Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
Published in: Investigational New Drugs | Issue 4/2012
Login to get access